Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €196.36 EUR
Change Today -0.50 / -0.25%
Volume 1.0
ILU On Other Exchanges
As of 3:00 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILU) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/15 - €200.00
52 Week Low
10/15/14 - €106.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ILLUMINA INC (ILU)

illumina inc (ILU) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $859.2K
President and Director
Total Annual Compensation: $689.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $463.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $403.7K
Compensation as of Fiscal Year 2014.

illumina inc (ILU) Key Developments

BioMed Realty Trust, Inc. Signs Lease Agreement with Illumina, Inc. for 155,000 Square Foot New and Innovative Scientific Research Building in Cambridge, England

BioMed Realty Trust Inc. announced that Illumina Inc. signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. The project will provide Illumina a collaborative environment and access to the highly skilled workforce in the dynamic research cluster anchored by Cambridge University. The project advances design, with plans to be able to seamlessly expand by 70,000 square feet into a 225,000 square foot building. BioMed Realty acquired the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty'sGranta Park campus in Cambridge, England. BioMed Realty owns, manages and operates Granta Park, a scientific research center, located eight miles from Cambridge University and currently comprising 472,200 square feet of laboratory and office space. Last year, the company acquired a 42,400 square foot build-to-suit property in development for Takeda Pharmaceutical Company in the Cambridge Science Park. With announcement of Illumina's new building, BioMed Realty's presence in the Cambridge, England market is approaching 700,000 square feet.

Annoroad Partners with Illumina to Co-Develop NGS Diagnostic System for Reproductive Health

Illumina revealed the launch of an agreement to develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology in China in joint partnership with Annoroad. NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine and this newly formed partnership signals the increasing importance of genomic applications to improve healthcare in China. This partnership will focus on providing the most advanced and integrated sequencing solutions to the clinical market as well as work together to develop a user-friendly, prenatal DNA diagnostic system for the Chinese market. The collaboration will bring together technology from Illumina sequencers with Annoroad's advanced clinical application development capabilities. Annoroad will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.

Merck KGaA, Illumina Inc. and Genea Limited Announce Formation of Global Fertility Alliance

Merck KGaA announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between the biopharmaceutical business of Merck, Illumina Inc. and Genea Limited. The alliance aims to improve the consistency in ART worldwide and addresses the need for more standardization of fertility processes within the ART laboratory. The three companies will launch their initiative at the 31st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lisbon, Portugal, on 13 June 2015. This is another important step for the biopharmaceuticals business of Merck, KGaA, towards establishing global standards in the growing market of fertility technologies and the ultimate goal of helping families to have a baby. With the establishment of the alliance, the biopharmaceuticals business of Merck, KGaA, Illumina and Genea emphasize their desire to help improve fertility outcomes by contributing to the standardization of technologies and protocols in ART labs. Currently, variation in practices and techniques can lead to inconsistent results and outcomes. Recognizing the importance of innovation in ART technologies the alliance aims to enhance progress and innovation in three ways: Firstly, the founding members aim to foster integration of multiple, leading fertility technologies. Secondly, building on this, the alliance will aim to collaborate with leading health care professionals and medical societies to develop global standards. And finally, as technologies in the fertility space are rapidly advancing, the alliance will also develop educational resources for health care professionals worldwide. These efforts will include training curricula and workshops as well as access to model labs, symposia and events at medical meetings.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILU:GR €196.36 EUR -0.50

ILU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $137.64 USD +2.14
Becton Dickinson and Co $143.18 USD -0.04
Hologic Inc $38.41 USD +0.28
Sigma-Aldrich Corp $139.48 USD +0.04
Waters Corp $129.37 USD +0.34
View Industry Companies

Industry Analysis


Industry Average

Valuation ILU Industry Range
Price/Earnings 76.0x
Price/Sales 16.0x
Price/Book 19.5x
Price/Cash Flow 67.3x
TEV/Sales 14.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at